Pfizer Inc: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 9, 2019 and accepted by EDGAR at May 9, 2019, 20:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-01-01 to 2019-03-31 | $13.12bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $2.43bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2019-01-01 to 2019-03-31 | $3.34bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2019-01-01 to 2019-03-31 | $361.0m | us-gaap:InterestExpense |
| Income tax | 3 months2019-01-01 to 2019-03-31 | $433.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | $3.88bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | $0.68 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-01-01 to 2019-03-31 | $0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-01-01 to 2019-03-31 | 5,750,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | $1.70bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-01-01 to 2019-03-31 | $460.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2019-01-01 to 2019-03-31 | $8.87bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-03-31 | $1.94bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $45.29bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $155.42bn | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $29.42bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $96.26bn | us-gaap:Liabilities |
| Long-term debt | At period end2019-03-31 | $35.73bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-03-31 | $4.47bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2019-03-31 | $3.95bn | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2019-03-31 | $58.81bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000078003-19-000026. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.